...
首页> 外文期刊>Journal of Pharmacy and Bioallied Sciences >Assesment of endocrinal and biochemical entities through liquid chromatography–tandem mass spectrometry/mass spectrometer: Inter-relative investigation of the interaction based cardiovascular formulation
【24h】

Assesment of endocrinal and biochemical entities through liquid chromatography–tandem mass spectrometry/mass spectrometer: Inter-relative investigation of the interaction based cardiovascular formulation

机译:通过液相色谱-串联质谱/质谱仪评估内分泌和生化实体:基于相互作用的心血管制剂的相互关系研究

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background:Combinatory oral dosage treatment of atorvastatin (ATVS) and olmesartan (OLM) drugs to cardiovascular patients reflects unpredicted results instead of its individual therapy, which was accessed on quantification of endocrinal and biochemicals of plasma through liquid chromatography–tandem mass spectrometry/mass spectrometer (LCMS/MS).Objective:Mission was to track the remarkable biochemical variation in the plasma after induction of the combined formulation, to evaluate the pharma-market rumor on its efficiency.Methods:To fulfil undergoing research objectives for digging-up of market insult, human patient volunteers were chosen according to the required criteria along with bioethical regulation. A sensitive, rapid and precise method was developed and validated to estimate aldosterone (ALD), angiotensin (ANG-II) and the Mevalonate (MVA) not Mevalonic acid through LCMS/MS over least samples of cardiovascular patients. Level of each endogenous biochemicals were determined in three stages - without drugs, with a single drug (OLM/ATVS) and with their combination that was then correlate with blood pressure of respective volunteers.Result and Discussion:Comparative and correlative studies panaroma among these analytes was detected. The selectivity, specificity, linearity, precision, accuracy, extraction recovery, limit of detection and limit of quantification, stability were the essential points of validation of the developed methodology. And the significance of each endogenous analyte data were based on P ≥ 0.001. Thus, low value of ALD and reciprocally higher in ANG-II on administered single drug than its combination and equal concentration of mevalonate in both stages, was discovered.Conclusion:This concludes that the cardiovascular dosage formulation entrenched in the market are not synergistic and effective compared with a single drug as antihypertensive drug.
机译:背景:阿托伐他汀(ATVS)和奥美沙坦(OLM)药物对心血管患者的联合口服剂量治疗反映了不可预测的结果,而不是其单独的治疗方法,该方法可通过液相色谱-串联质谱/质谱法定量分析血浆内分泌和生化成分(LCMS / MS)。目的:任务是跟踪组合制剂诱导后血浆中显着的生化变化,以评估制药市场谣言的有效性。方法:完成正在进行的研究以挖掘市场侮辱,根据所需标准以及生物伦理规范选择了人类患者志愿者。开发了一种灵敏,快速且精确的方法,并通过LCMS / MS对至少部分心血管疾病患者的醛固酮(ALD),血管紧张素(ANG-II)和甲羟戊酸(MVA)而非甲羟戊酸进行了估算。每种内源性生化试剂的水平分三个阶段进行测定-不使用药物,仅使用一种药物(OLM / ATVS)以及其组合与各自志愿者的血压相关联。结果与讨论:这些分析物之间的对比和相关研究被检测到。选择性,特异性,线性,精密度,准确度,提取回收率,检出限和定量限,稳定性是开发方法论验证的关键。每个内源分析物数据的显着性均基于P≥0.001。因此,发现在两个阶段中,ALD的价值较低,并且在单用药物中ANG-II的含量高于其组合和甲羟戊酸的相等浓度。结论:结论是,市场上根深蒂固的心血管剂型不是协同有效的与单一药物作为降压药相比。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号